Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
targeted therapies
Pharma
In a first, FDA approves Servier's Voranigo in low-grade gliomas
Servier's Voranigo, or vorasidenib, is now the first systemic therapy for low-grade IDH-mutant brain cancer.
Angus Liu
Aug 6, 2024 5:25pm
FDA clears Bristol Myers cancer drug from Turning Point buy
Nov 16, 2023 11:10am
ESMO: Roche's Alecensa cuts postsurgery lung cancer recurrence
Oct 21, 2023 10:30am
Roche pulls a Gavreto cancer indication, citing unfeasible trial
Jul 5, 2023 12:16pm
Lilly, Merck bet billions in biobucks on peptide-based delivery
Jan 3, 2023 8:40am
ASCO: J&J touts Balversa's pan-tumor power, plots FDA talks
May 26, 2022 5:00pm
